Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.49% to 4160.01, the Shenzhen Component Index increasing by 0.09% to 14342.74, and the ChiNext Index declining by 0.37% to 3330.39 [1][2]. Sector Performance - Precious metals, industrial metals, and petrochemicals sectors performed strongly, while solar energy, pharmaceuticals, and aerospace sectors experienced fluctuations [2]. - The basic metals sector saw significant gains, with copper and aluminum industries leading the rise, as multiple stocks hit the daily limit up [6]. Stock Highlights - Notable stocks included China National Offshore Oil Corporation, China Petroleum, and China Unicom, which showed strong performance [4]. - The aluminum futures market saw a rise of over 4%, with the main contract reported at 25345 yuan/ton [8]. Biotechnology Sector - The biotechnology sector faced declines, with several companies such as Zhijiang Biology and Baipusais losing over 9% [10][11]. Solar Energy Sector - The solar energy sector faced downward adjustments, with companies like High Measurement and Maiwei experiencing drops exceeding 6% [11].

Group 1 - The restructuring of the protein sector led to a decline of 1.42% [1] - Companies such as Baipusais fell by 7.3%, indicating significant losses within the sector [1] - Other companies like Nearshore Protein and Haitai Bio also experienced declines of 2.81% and 2.16% respectively [1] Group 2 - Sanofi Guojian saw a drop of over 3%, contributing to the overall downturn in the protein sector [1]

百普赛斯公告，公司已于2026年1月26日向香港联合交易所有限公司递交了发行境外上市股份(H股)并在 香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 ...

鉴于本次发行上市的认购对象将仅限于符合相关条件的境外投资者及依据 中国相关法律法规有权进行境外证券投资的境内合格投资者，公司将不会在境内 证券交易所的网站和符合境内监管机构规定条件的媒体上刊登该申请资料，但为 使境内投资者及时了解该等申请资料披露的本次发行上市以及公司的其他相关 信息，现提供该申请资料在香港联交所网站的查询链接供查阅： 证券代码：301080 证券简称：百普赛斯 公告编号：2026-002 北京百普赛斯生物科技股份有限公司 关于向香港联交所递交境外上市股份(H 股)发行上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）已于 2026 年 1 月 26 日向香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境 外上市股份（H 股）并在香港联交所主板挂牌上市（以下简称"本次发行上市"） 的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 该申请材料为公司按照香港证券及期货事务监察委员会（以下简称"香港证 监会"）及香港联交所的要求编制和刊发，为草拟 ...

Company Overview - Beijing Baipusi Biotechnology Co., Ltd. (Baipusi) has submitted its listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a leading player in the biological reagent industry, particularly in the recombinant protein segment, ranking first among domestic suppliers in China and third globally by revenue in 2024 [1][3] - The company offers a comprehensive product portfolio that includes high-quality biological reagents and various technical services, supporting the entire value chain of biopharmaceutical companies from R&D to clinical applications [3][5] Financial Performance - For the fiscal year 2023, Baipusi reported revenues of approximately RMB 544 million, with projected revenues of RMB 645 million for 2024 and RMB 613 million for the nine months ending September 30, 2025 [6][10] - The gross profit for 2023 was around RMB 459 million, with a gross margin of 84.3%, and is expected to maintain a gross margin of approximately 82.2% in 2025 [8][10] - The company recorded a profit of approximately RMB 148 million for 2023, with a projected profit of RMB 132 million for the nine months ending September 30, 2025 [10][11] Market Overview - The global life sciences tools market reached USD 32.1 billion in 2020 and is projected to grow at a CAGR of 5.2% to USD 39.3 billion by 2024, further expanding to USD 61 billion by 2030 [12] - The biological reagent market, which includes products and services, was valued at USD 18.2 billion in 2020, with expectations to grow to USD 25.1 billion by 2024, and USD 35.6 billion by 2030 [14][16] - The recombinant protein market is anticipated to grow from USD 1 billion in 2020 to USD 3 billion by 2024, with a CAGR of 31.9%, and further to USD 7.8 billion by 2030 [18][19] Business Model - Baipusi operates on a "dual-engine" business model in China and the United States, allowing it to acquire advanced technological knowledge and efficient production capabilities [5] - The company serves a diverse clientele, including the top 20 global pharmaceutical companies and the top five life sciences service providers, with a 100% repurchase rate from its top clients [5][6] - Baipusi's production facilities in Beijing and Suzhou comply with international quality standards, including ISO certifications and GMP [6]

Group 1 - The core viewpoint of the news is that Beijing Baipusi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a global provider of life science tools and technology services, focusing on empowering biopharmaceutical companies across the entire value chain of research and development, production, and clinical applications [1] - According to Frost & Sullivan, Baipusi ranks first among all domestic suppliers in China and third globally in the recombinant protein market based on revenue projected for 2024 [1]

Group 1 - The core point of the article is that Beijing Baipusi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusi is a global provider of life science tools and technology services, focusing on empowering biopharmaceutical companies across the entire value chain of research and development, production, and clinical applications [1] - According to Frost & Sullivan, Baipusi ranks first among all domestic suppliers in China and third globally in the recombinant protein market based on revenue projected for 2024 [1]

Group 1 - The core viewpoint of the article is that Beijing Baipusais Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CMB International as its sole sponsor [1] - Baipusais is a global provider of life science tools and technology services, focusing on empowering biopharmaceutical companies across the entire value chain of research and development, production, and clinical applications [1] - According to Frost & Sullivan, Baipusais ranks first among all domestic suppliers in China and third globally in the recombinant protein market based on projected revenue for 2024 [1]

格隆汇1月26日｜据港交所文件，北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

据港交所文件：北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...